EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia